Venus Remedies gets Japan patent office’s approval for Vancoplus

06 Feb 2012 Evaluate

Venus Remedies has achieved another landmark by fetching its first patent grant from Japan patent office (JPO) which is among the most stringent pharma market in the world. This patent has been granted for its novel research product Vancoplus which has been designed to curb the growing bacterial resistance specially caused by the notorious MRSA strain which is usually termed as one of the Superbugs.

During the past four decades, Methicillin- Resistant Staphylococcus Aureus (MRSA) has evolved from a controllable nuisance into a serious public health concern. Vancoplus is the only known remedy to control MRSA, VRSA (Vancomycin Resistant Staphylococcus Aureus) and multi drug resistant bacteria which causes meningitis, pneumonia, typhoid, septicemia, urinary tract infection, skin and skin infections and staphylococcal endocarditic.

The market size of MRSA in the world accounts for about $900 million, presently, it is growing with CAGR of 4.8 percent, which is estimated to reach to $1.2 billion by 2017.

The company intends to launch this research product in early 2015. Currently, Vancoplus is available in emerging markets and is under registration ion many countries. Venus intends to out-license Vanocoplus across patent protected regions to major pharmaceutical players.

Venus Remedies Share Price

745.20 -7.70 (-1.02%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×